A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens

INTRODUCTION: Omalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD‐sens) has been shown to correlate with the bronchial allergen threshold sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, S. Gunnar O., Lilja, Gunnar, Hallberg, Jenny, Nopp, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113766/
https://www.ncbi.nlm.nih.gov/pubmed/29737044
http://dx.doi.org/10.1002/iid3.225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113766/
https://www.ncbi.nlm.nih.gov/pubmed/29737044
http://dx.doi.org/10.1002/iid3.225

Ejemplares similares